Search
forResearch 10 of 398
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Alopecia areata and ritlecitinib: Unravelling response trajectories
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →